Advertisement
Canadian Journal of Cardiology

Comparison of 10 mg and 25 mg of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction

      Although large trials
      • Packer M.
      • Anker S.D.
      • Butler J.
      • et al.
      Cardiovascular and renal outcomes with empagliflozin in heart failure.
      ,
      • McMurray J.J.V.
      • Solomon S.D.
      • Inzucchi S.E.
      • et al.
      Dapagliflozin in patients with heart failure and reduced ejection fraction.
      suggested that sodium-glucose cotransporter-2 (SGLT2) inhibitors could ameliorate the prognosis of patients with heart failure (HF) with reduced ejection fraction (HFrEF), it is uncertain whether the effects of different doses of empagliflozin on HFrEF patients are the same. The objective of this study was to compare the effects of 10 mg and 25 mg of empagliflozin on the prognosis of HFrEF patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Packer M.
        • Anker S.D.
        • Butler J.
        • et al.
        Cardiovascular and renal outcomes with empagliflozin in heart failure.
        N Engl J Med. 2020; 383: 1413-1424
        • McMurray J.J.V.
        • Solomon S.D.
        • Inzucchi S.E.
        • et al.
        Dapagliflozin in patients with heart failure and reduced ejection fraction.
        N Engl J Med. 2019; 381: 1995-2008
        • Shi F.H.
        • Li H.
        • Shen L.
        • et al.
        High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: a meta-analysis of randomized clinical trials.
        Diabetes Obes Metab. 2021; 23: 2125-2136